Radient Pharmaceuticals Corporation fka RXPC

[Future Doc]

@ Gold Do you agree that the most likely reason for this mention and sought approval for a R/S is to have an option that can artificially raise share prices when exercised? This is what I gather from the AMEX de-listing notice which include the "1.00 or above" requirement violation. I am inclined to believe that if the Mayo clinic results are good AND a significant influx of orders is seen, or at least pre-orders, then there won't be a need for the R/S. What are your opinions regarding this specific hypothetical situation? Thanks in advance.